{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:38:21Z","timestamp":1787506701602,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.beem.2013.10.004","type":"journal-article","created":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T11:45:59Z","timestamp":1382787959000},"page":"387-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children"],"prefix":"10.1016","volume":"28","author":[{"given":"Michael M.","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon A.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beem.2013.10.004_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.beem.2013.10.004_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.beem.2013.10.004_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1469-1809.2012.00724.x","article-title":"Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment","volume":"76","author":"Usifo","year":"2012","journal-title":"Ann Hum Genet"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A\u00a0review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2013.10.004_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia","volume":"12","author":"Watts","year":"2011","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI109490","article-title":"Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in\u00a0vivo","volume":"64","author":"Bilheimer","year":"1979","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0021-9150(94)05430-Q","article-title":"Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study","volume":"113","author":"Cummings","year":"1995","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.beem.2013.10.004_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.ATV.0000155323.18856.a2","article-title":"Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production","volume":"25","author":"Millar","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.beem.2013.10.004_bib10","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ijcard.2013.06.069","article-title":"The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies","volume":"168","author":"Ooi","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.beem.2013.10.004_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajmg.1320340418","article-title":"Prevalence of familial hypercholesterolemia in Johannesburg Jews","volume":"34","author":"Seftel","year":"1989","journal-title":"Am J Med Genet"},{"issue":"6241","key":"10.1016\/j.beem.2013.10.004_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.281.6241.633","article-title":"A\u00a0host of hypercholesterolaemic homozygotes in South Africa","volume":"281","author":"Seftel","year":"1980","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2010.11.006","article-title":"Homozygous familial hypercholesterolemia in Lebanon: a genotype\/phenotype correlation","volume":"102","author":"Fahed","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Quebec Province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis"},{"issue":"8","key":"10.1016\/j.beem.2013.10.004_bib15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.ATV.16.8.984","article-title":"Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects","volume":"16","author":"Tonstad","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9406","key":"10.1016\/j.beem.2013.10.004_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","article-title":"Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia","volume":"363","author":"Wiegman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2013.10.004_bib17","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50 Suppl.","author":"Horton","year":"2009","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000175431","article-title":"Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients","volume":"15","author":"Khachadurian","year":"1973","journal-title":"Nutr Metab"},{"issue":"6","key":"10.1016\/j.beem.2013.10.004_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/01.CIR.98.6.509","article-title":"Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia","volume":"98","author":"Summers","year":"1998","journal-title":"Circulation"},{"issue":"6807","key":"10.1016\/j.beem.2013.10.004_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1016\/j.beem.2013.10.004_bib21","series-title":"Familial hypercholesterolemia. Report of a second WHO Consultation","author":"World Health Organization","year":"1999"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.beem.2013.10.004_bib23","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2013.10.004_bib25","article-title":"Principles and practice of screening for disease","author":"Wilson","year":"1968","journal-title":"World Health Organization"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/PAT.0b013e32834efa07","article-title":"Screening for familial hypercholesterolaemia","volume":"44","author":"Bender","year":"2012","journal-title":"Pathology"},{"key":"10.1016\/j.beem.2013.10.004_bib27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1258\/acb.2012.012002","article-title":"Opportunistic screening for familial hypercholesterolaemia via a community laboratory","volume":"49","author":"Bell","year":"2012","journal-title":"Ann Clin Biochem"},{"issue":"3 Suppl.","key":"10.1016\/j.beem.2013.10.004_bib28","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jacl.2011.04.001","article-title":"Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Ito","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"issue":"20","key":"10.1016\/j.beem.2013.10.004_bib29","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.beem.2013.10.004_bib30","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2013.10.004_bib31","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"7","key":"10.1016\/j.beem.2013.10.004_bib32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5551\/jat.4143","article-title":"Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia","volume":"17","author":"Harada-Shiba","year":"2010","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2011.03.027","article-title":"Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades","volume":"108","author":"Elis","year":"2011","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.beem.2013.10.004_bib34","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.beem.2013.10.004_bib35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.beem.2013.10.004_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MOT.0b013e3283399dbd","article-title":"Liver transplantation for inherited metabolic disorders of the liver","volume":"15","author":"Moini","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosissup.2012.10.001","article-title":"The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease","volume":"14","author":"Thompson","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"10.1016\/j.beem.2013.10.004_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","article-title":"Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe","volume":"21","author":"Thompson","year":"2010","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.beem.2013.10.004_bib40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOL.0b013e32833e13fd","article-title":"Lipoprotein apheresis","volume":"21","author":"Thompson","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.beem.2013.10.004_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2013.10.004_bib42","doi-asserted-by":"crossref","first-page":"314283","DOI":"10.1100\/2012\/314283","article-title":"LDL-apheresis: technical and clinical aspects","volume":"2012","author":"Bambauer","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"5","key":"10.1016\/j.beem.2013.10.004_bib43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14779072.6.5.629","article-title":"Comparison of different LDL apheresis methods","volume":"6","author":"Julius","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2013.10.004_bib46","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0022-2275(20)32381-6","article-title":"Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia","volume":"41","author":"Schamberger","year":"2000","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.10.004_bib47","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjcard.2007.06.033","article-title":"Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol","volume":"100","author":"Opole","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beem.2013.10.004_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1567-5688(09)71811-2","article-title":"Pleiotropic effects of LDL apheresis","volume":"10","author":"Ramunni","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.beem.2013.10.004_bib49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cyto.2011.08.027","article-title":"Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia","volume":"56","author":"Stefanutti","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2013.10.004_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.95.1.76","article-title":"Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans","volume":"95","author":"Tamai","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.10.004_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/CH-2009-1166","article-title":"Long-term LDL apheresis does not stably improve hemorheology in hypercholesterolemic patients with coronary artery disease","volume":"41","author":"Pusl","year":"2009","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.beem.2013.10.004_bib52","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jca.20256","article-title":"Hematologic and hemostatic changes induced by different columns during LDL apheresis","volume":"25","author":"Hovland","year":"2010","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.beem.2013.10.004_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/jca.20223","article-title":"Different inflammatory responses induced by three LDL-lowering apheresis columns","volume":"24","author":"Hovland","year":"2009","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.beem.2013.10.004_bib54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1567-5688(09)71807-0","article-title":"Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques","volume":"10","author":"Kopprasch","year":"2009","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0735-1097(02)01955-1","article-title":"Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART)","volume":"40","author":"Matsuzaki","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.beem.2013.10.004_bib56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0026-0495(98)90127-5","article-title":"Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia","volume":"47","author":"Richter","year":"1998","journal-title":"Metab Clin Exp"},{"issue":"8","key":"10.1016\/j.beem.2013.10.004_bib57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.STR.22.8.989","article-title":"Regression of carotid plaques during low density lipoprotein cholesterol elimination","volume":"22","author":"Hennerici","year":"1991","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2796.1999.00466.x","article-title":"Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients","volume":"246","author":"Koga","year":"1999","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2013.10.004_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/(SICI)1098-1101(1997)12:4<202::AID-JCA10>3.0.CO;2-T","article-title":"Long-term follow-up of carotid atherosclerosis in patients with heterozygous familial hypercholesterolemia under LDL apheresis treatment","volume":"12","author":"Donner","year":"1997","journal-title":"J\u00a0Clin Apher"},{"issue":"7","key":"10.1016\/j.beem.2013.10.004_bib60","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1537-2995.2009.02135.x","article-title":"Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis","volume":"49","author":"Stefanutti","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.beem.2013.10.004_bib61","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","article-title":"Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis","volume":"345","author":"Thompson","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2013.10.004_bib62","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.beem.2013.10.004_bib63","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0735-1097(96)00388-9","article-title":"Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease","volume":"28","author":"Aengevaeren","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03195256","article-title":"Clinical course of homozygous familial hypercholesterolemia during childhood: report on 4 unrelated patients with homozygous or compound heterozygous mutations in the LDLR gene","volume":"49","author":"Kubalska","year":"2008","journal-title":"J\u00a0Appl Genet"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1744-9987.2009.00747.x","article-title":"Retrospective analysis of long-term lipid apheresis at a single center","volume":"14","author":"Koziolek","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.beem.2013.10.004_bib66","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.beem.2013.10.004_bib67","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/clp.09.7","article-title":"LDL apheresis for familial hypercholesterolemia: value, indications and demand","volume":"4","author":"Watts","year":"2009","journal-title":"Clin Lipidol"},{"issue":"3","key":"10.1016\/j.beem.2013.10.004_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1744-9987.2008.00574.x","article-title":"Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years","volume":"12","author":"Palcoux","year":"2008","journal-title":"Ther Apher Dial"},{"issue":"6","key":"10.1016\/j.beem.2013.10.004_bib70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11594970-000000000-00000","article-title":"Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia","volume":"11","author":"Lee","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacl.2011.12.003","article-title":"The use of lipopheresis in the practice of clinical lipidology","volume":"6","author":"Brown","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"issue":"5","key":"10.1016\/j.beem.2013.10.004_bib72","first-page":"1","article-title":"Low-density lipoprotein apheresis: an evidence-based analysis","volume":"7","author":"Health Quality Ontario","year":"2007","journal-title":"Ontario Health Technol Assess Ser"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.beem.2013.10.004_bib74","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.beem.2013.10.004_bib75","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2008.06.049","article-title":"Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia","volume":"102","author":"Hudgins","year":"2008","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.beem.2013.10.004_bib76","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MOL.0b013e32836308bc","article-title":"Recent advances in the treatment of homozygous familial hypercholesterolaemia","volume":"24","author":"Marais","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.beem.2013.10.004_bib77","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"10.1016\/j.beem.2013.10.004_bib78","article-title":"Clinical utility gene card for: familial Hypobetalipoproteinaemia (APOB)","volume":"20","author":"Burnett","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.beem.2013.10.004_bib79","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/01.ATV.0000176191.64314.07","article-title":"Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia","volume":"25","author":"Sankatsing","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"10.1016\/j.beem.2013.10.004_bib80","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.beem.2013.10.004_bib81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MOL.0b013e328362dfd9","article-title":"Is mipomersen ready for clinical implementation? A transatlantic dilemma","volume":"24","author":"Sjouke","year":"2013","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"10.1016\/j.beem.2013.10.004_bib82","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.beem.2013.10.004_bib83","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.beem.2013.10.004_bib84","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"issue":"9719","key":"10.1016\/j.beem.2013.10.004_bib85","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.beem.2013.10.004_bib86","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib87","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.beem.2013.10.004_bib88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14712598.2012.748743","article-title":"Anti-PCSK9 therapies for the treatment of hypercholesterolemia","volume":"13","author":"Hooper","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.beem.2013.10.004_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.beem.2013.10.004_bib90","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.10.004_bib91","series-title":"European Atherosclerosis Society; 2\u20135 June; Lyon","article-title":"Trial evaluating AMG 145, a PCSK9 antibody, in patients with homozygous FH: results of an initial dose-scheduling study","author":"Stein","year":"2013"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib92","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.beem.2013.10.004_bib93","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2013.10.004_bib94","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-7075-9-14","article-title":"Multiple functions of microsomal triglyceride transfer protein","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr Metab (Lond)"},{"issue":"8","key":"10.1016\/j.beem.2013.10.004_bib95","article-title":"Clinical utility gene card for: abetalipoproteinaemia","volume":"20","author":"Burnett","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.beem.2013.10.004_bib96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9860","key":"10.1016\/j.beem.2013.10.004_bib97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beem.2013.10.004_bib98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5551\/jat.11.110","article-title":"Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese","volume":"11","author":"Nagano","year":"2004","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"22","key":"10.1016\/j.beem.2013.10.004_bib99","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.beem.2013.10.004_bib100","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.beem.2013.10.004_bib101","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2013.10.004_bib102","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12265-011-9311-1","article-title":"Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively","volume":"5","author":"Ibrahim","year":"2012","journal-title":"J\u00a0Cardiovasc Translational Res"},{"issue":"4","key":"10.1016\/j.beem.2013.10.004_bib103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacl.2011.05.002","article-title":"Fatal cardiac atherosclerosis in a child 10 years after liver transplantation: a case report and review","volume":"5","author":"El-Rassi","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.beem.2013.10.004_bib104","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.2174\/138161211797247550","article-title":"Gene therapy for familial hypercholesterolaemia","volume":"17","author":"Van Craeyveld","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.beem.2013.10.004_bib105","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A\u00a0pilot study of ex\u00a0vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib106","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2012.108","article-title":"Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia","volume":"24","author":"Kassim","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.beem.2013.10.004_bib107","first-page":"11","article-title":"Common and rare gene variants affecting plasma LDL cholesterol","volume":"29","author":"Burnett","year":"2008","journal-title":"Clin Biochemist Rev"},{"key":"10.1016\/j.beem.2013.10.004_bib108","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jca.20299","article-title":"Lipid apheresis, indications, and principles","volume":"26","author":"Winters","year":"2011","journal-title":"J\u00a0Clin Apher"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2013.10.004_bib109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11789-012-0046-6","article-title":"Current view: indications for extracorporeal lipid apheresis treatment","volume":"7","author":"Schettler","year":"2012","journal-title":"Clin Res Cardiol Suppl"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13001541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13001541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:48:47Z","timestamp":1761497327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X13001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521690X13001541"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2013.10.004","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2013.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}